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SUMMARY

Kelch-like ECH-associated protein 1 (Keap1) is a
ubiquitin E3 ligase specificity factor that targets
transcription factor nuclear factor (erythroid-derived
2)-like 2 (Nrf2) for ubiquitination and degradation.
Disrupting Keap1-Nrf2 interaction stabilizes Nrf2,
resulting in Nrf2 nuclear accumulation, binding to
antioxidant response elements (AREs), and transcription of cytoprotective genes. Marburg virus
(MARV) is a zoonotic pathogen that likely uses bats
as reservoir hosts. We demonstrate that MARV
protein VP24 (mVP24) binds the Kelch domain of
either human or bat Keap1. This binding is of high
affinity and 1:1 stoichiometry and activates Nrf2.
Modeling based on the Zaire ebolavirus (EBOV)
VP24 (eVP24) structure identified in mVP24 an acidic
loop (K-loop) critical for Keap1 interaction. Transfer
of the K-loop to eVP24, which otherwise does not
bind Keap1, confers Keap1 binding and Nrf2 activation, and infection by MARV, but not EBOV, activates ARE gene expression. Therefore, MARV
targets Keap1 to activate Nrf2-induced cytoprotective responses during infection.
INTRODUCTION
Kelch-like ECH-associated protein 1 (Keap1) is a cellular adaptor
protein that links the Cul3/Rbx1 (Roc1) ubiquitin E3 ligase to the
oxidative stress response through its interaction with the transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2)
(reviewed in Copple, 2012). Under homeostatic conditions,
Keap1 suppresses the cellular antioxidant transcriptional program by directing the ubiquitin-mediated degradation of Nrf2
(Itoh et al., 1999; McMahon et al., 2003). Keap1 interacts, via
its Kelch domain, with two sites located in the Nrf2-ECH homol-

ogy-2 (Neh2) domain of Nrf2 (Itoh et al., 1999; Tong et al., 2006).
Disruption of Nrf2-Keap1 interaction leads to transcription
of genes possessing antioxidant response elements (AREs)
(Tong et al., 2007). The upregulated ARE genes encode proteins
involved in detoxification reactions, cell survival, and immune
modulation (reviewed in Baird and Dinkova-Kostova, 2011; Ma,
2013).
ARE responses impact the outcome of viral infections. For
example, the Nrf2 pathway inhibits influenza virus and respiratory syncytial virus replication in cell culture and in vivo (Cho
et al., 2009; Kesic et al., 2011). In contrast, for hepatitis B virus,
hepatitis C virus, and human cytomegalovirus, induction of ARE
responses may protect infected cells from oxidative damage and
influence immune responses by modulating immunoproteasome
function (Burdette et al., 2010; Ivanov et al., 2011; Lee et al.,
2013; Schaedler et al., 2010).
Marburg viruses (MARVs) and Ebola viruses (EBOVs),
members of the family Filoviridae, are emerging, zoonotic
pathogens that likely use bats as reservoir hosts. Filoviruses
are of concern because they cause hemorrhagic fever with a
high fatality rate in humans (reviewed in Brauburger et al.,
2012). Filoviruses encode multifunctional VP24 proteins, which
play important roles in the formation of viral nucleocapsids,
release of infectious virus particles, and modulation of viral
RNA synthesis (Bamberg et al., 2005; Beniac et al., 2012;
Bharat et al., 2011, 2012; Hoenen et al., 2006; Huang et al.,
2002; Mateo et al., 2011; Noda et al., 2006; Watanabe et al.,
2007; Wenigenrath et al., 2010). In addition, EBOV VP24
(eVP24) disrupts interferon (IFN) signaling pathways and
interacts with select karyopherin a proteins (KPNAs), thereby
blocking nuclear accumulation of tyrosine-phosphorylated
STAT1 (Mateo et al., 2010; Reid et al., 2006, 2007). In contrast,
MARV VP24 (mVP24) neither interacts with KPNAs nor inhibits
IFN signaling, and functionally relevant interactions with host
factors have not previously been defined (Valmas et al.,
2010). However, a recent mass spectrometry screen identified
Keap1 as a potential mVP24 binding partner (Pichlmair et al.,
2012).
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Figure 1. mVP24 Interacts with Keap1 in CoIP Assays
(A) coIPs with HA antibody were performed on lysates of HEK293T cells cotransfected with plasmids for Flag-Keap1 and HA-mVP24 or HA-eVP24. Western blots
were performed for Flag and HA. WCL, whole cell lysate; IP, immunoprecipitation.
(B) Schematic diagram of Flag-tagged Keap1 domain deletion mutants used in (C).
(C) Flag-Keap1 domain deletion mutant constructs were coexpressed in HEK293T cells with HA-mVP24 and analyzed by coIP with Flag antibody.
(D) HA-mVP24 and either Flag-Keap1 or Flag-Keap1 R415A were analyzed by coIP as in (C).
(E) Overlay of the mVP24 structural model (orange) on the determined eVP24 structure (purple). The mVP24 K-loop (amino acids 205–212) is indicated in red.

(legend continued on next page)
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To date, the described mechanisms by which viruses engage
the ARE response do not involve direct interaction with components of the signaling pathways. Rather, viruses are demonstrated to activate other signaling pathways or induce oxidative
stress, indirectly activating antioxidant responses. Here, we
demonstrate that mVP24 but not eVP24 directly interacts
with the human and bat Keap1 proteins. We further define
the basis of the interaction and demonstrate that expression
of mVP24 but not eVP24 activates Nrf2, triggering cytoprotective responses. Correspondingly, MARV but not EBOV
infection activates ARE gene expression. Collectively, these
data suggest that MARV evolved to specifically target a
host cytoprotective gene expression program to facilitate its
replication.
RESULTS
mVP24 Interacts with Keap1
Coimmunoprecipitation (coIP) assays demonstrated that Flagtagged Keap1 interacts with HA-mVP24, but not with HAeVP24 (Figure 1A). Keap1 contains several previously defined
domains: the N-terminal region (NTR); the Bric-a-Brac, Tramtrack, Broad complex (BTB) domain; the intervening region
(IVR); and the Kelch domain/C-terminal region (CTR) (Komatsu
et al., 2010). Domain deletion mutants of Keap1 and a
construct comprising only the Kelch domain/CTR were tested
for mVP24 interaction by coIP (Figure 1B). The NTR and IVR
deletion mutants retained interaction, whereas deletion of
the Kelch/CTR resulted in loss of interaction (Figure 1C). The
isolated Kelch/CTR domain also interacted with mVP24 (Figure 1C). Therefore, the Kelch/CTR domain is necessary and
sufficient to interact with mVP24 (Figure 1C). The mutation to
alanine of Keap1 Kelch domain residue R415 disrupts interaction with Nrf2 (Lo et al., 2006). Similarly, Keap1 R415A did not
coprecipitate with mVP24 (Figure 1D), suggesting that Nrf2
and mVP24 interact with the Keap1 Kelch region in a similar
fashion.
To gain insight into the region(s) of mVP24 required to interact
with Keap1, we used our recently solved structure of VP24 from
Zaire EBOV, which is very similar to the structures of Sudan and
Reston eVP24s (Zhang et al., 2012) (see Supplemental Experimental Procedures, Supplemental Results, and Table S1), and
the Phyre2 software package to obtain a molecular model of
mVP24 (Kelley and Sternberg, 2009). The resulting structural
model identified a loop (the K-loop, amino acids 202–212) that
is likely solvent exposed (Figure 1E). The sequence near the
K-loop is not well conserved among filoviral VP24 proteins.
This loop contains a sequence DIEPCCGE that is reminiscent
of the high-affinity binding motif of DXXTGE, used by Nrf2 to
interact with the Keap1 Kelch domain (Lo et al., 2006). Among
the several Keap1 Kelch domain binding determinants, ‘‘GE’’
motifs appear to be the most highly conserved, with nearby
upstream acidic residues also playing an important role for

several interacting partners (Komatsu et al., 2010; Padmanabhan et al., 2008). Given this similarity, we made three HA-tagged
mVP24 constructs (Figure 1F). In ‘‘mVP24 linker,’’ the 205DIEPCCGE-212 sequence was replaced with a serine-glycine
linker. ‘‘mVP24 D205A/E207A’’ and ‘‘mVP24 G211A/E212A’’
were designed based on analogous loss-of-binding mutants
described for cellular Keap1-interactor p62 (Komatsu et al.,
2010). By coIP, wild-type mVP24 strongly interacted with
Keap1, mVP24 D205A/E207A interacted weakly, and no interaction was detected with either mVP24 linker or mVP24 G211A/
E212A (Figure 1F). To assess the role of the DIEPCCGE motif
for interaction with Keap1, DIEPCCGE was swapped in place
of the corresponding residues within eVP24, creating ‘‘eVP24
DIEPCCGE.’’ We also replaced the loop of eVP24 (202QEPDKSAMDIRHPGPV-217) with the mVP24 K-loop (202RRIDIEPCCGETVLSESV-219), creating the ‘‘eVP24 K-loop.’’
eVP24 DIEPCCGE and eVP24 K-loop interacted with Keap1,
with the full K-loop appearing to confer better binding, whereas
wild-type eVP24 once again did not interact with Keap1
(Figure 1G). These results demonstrate that the DIEPCCGE
sequence and the K-loop, when placed in the context of the
VP24 structural scaffold, play a critical role for mVP24-Keap1
interaction.
MARVs likely use bats as reservoir hosts (Amman et al., 2012;
Towner et al., 2009). Therefore, a specific viral interaction with
Keap1 likely evolved and should be conserved in bats. Alignment
of human Keap1 and two divergent bat species, a microbat
(Myotis lucifugus) and a megabat (Pteropus alecto), revealed
97% amino acid identity between human and microbat Keap1
and 98% amino acid identity between human and megabat
Keap1 (data not shown). Full-length Keap1 (bat-Keap1) and
Kelch domain (bat-Kelch) constructs were generated from
an available microbat (Myotis velifer incautus) cell line. Both
coprecipitate with mVP24 with efficiencies similar to that of
human Keap1 (Figure 1H).
Keap1 inhibits ARE gene expression through its interaction
with Nrf2 (McMahon et al., 2003). When Keap1 repression is
relieved, which can be due to posttranslational modification of
Keap1 or interaction with select Kelch domain binding partners
such as p62, Nrf2 translocates to the nucleus and activates
ARE gene expression (Itoh et al., 1999; McMahon et al., 2003).
To determine whether the interaction of mVP24 with the Keap1
Kelch domain activates Nrf2, a GFP-Nrf2 fusion protein was
expressed alone or in the presence of Flag-Keap1 and HAtagged wild-type mVP24, mutant mVP24 or wild-type, or
chimeric eVP24s. Overexpression of Nrf2, which is known to
overwhelm the available endogenous Keap1, resulted in nuclear
localization of GFP-Nrf2, as expected (Figure S1). Coexpression
of Keap1 retained most of the Nrf2 in the cytoplasm. Additional
expression of mVP24 and eVP24-K-loop restored Nrf2-GFP
nuclear localization, whereas mVP24 mutants and eVP24DIEPCCGE, which do not interact efficiently with Keap1, did
not (Figure S1; see Supplemental Results for details).

(F) Flag-Keap1 and HA-mVP24 wild-type or mutants were analyzed by coIP as in (A) and (C).
(G) Flag-Keap1 and HA-mVP24, eVP24, eVP24 DIEPCCGE, or eVP24 K-loop were coexpressed in HEK293T cells and analyzed by coIP as in (A).
(H) Flag-mVP24 and HA-Keap1, bat-Keap1, and bat-Kelch were coexpressed in HEK293T cells and analyzed by coIP as in (C).
See also Figure S1.
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Figure 2. mVP24 Binds to Keap1 Kelch
Domain with High Affinity and Specificity
(A and B) Representative ITC data for Kelch
domain of Keap1 binding to (A) Nrf2 Neh2 domain
and (B) mVP24. Raw heats of reaction versus time
(top panels) and the integrated heats of reaction
versus molar ratio of ligand to receptor (bottom
panels) are shown. Thermodynamic binding parameters of KD = 170 ± 60 nM, DH = 1.96 ± 0.1 3
104 kcal/mol, TDS = 10.4 kcal/mol, and n (no. of
sites) = 0.49 ± 0.02 for (A) and KD = 158 ± 20 nM,
DH = 2.10 ± 0.03 3 104 kcal/mol, TDS =
11.7 kcal/mol, and n (no. of sites) = 1.00 ± 0.01
for (B) were obtained.
(C) mVP24 binding to Kelch prevents Nrf2-Neh2
interaction. Coomassie blue-stained SDS-PAGE
of a pull-down assay where MBP-mVP24 was
immobilized on amylose resin (BB, bound beads)
is shown. Keap1 Kelch and Nrf2 Neh2 domain
were subsequently added to the resin (I, input),
and the resin was washed with buffer (washes).
The final bound bead sample (FB, final beads) is
indicated. M, molecular weight marker.
See also Figure S2.

FB

Kelch domain. Next, we assessed
whether mVP24 can outcompete Neh2
MBP-Marburg VP24
binding to the Kelch domain. A complex
between the Kelch domain and Neh2
Keap1 Kelch
was preformed, and the ability of an
immobilized mVP24 protein to displace
Neh2 from the Kelch/Neh2 complex
was assessed. Despite similar affinities
of Neh2 and mVP24 for Kelch domain,
Nrf2 Neh2
mVP24 can bind the Kelch domain in
the presence of a 2-fold excess of
Neh2 (Figure 2C). Therefore, in the
absence of other factors, mVP24 displaces Nrf2 from Keap1. This provides a
mVP24 Binds the Keap1 Kelch Domain with High Affinity
biochemical explanation as to how the mVP24-Keap1 interand Specificity
action triggers Nrf2 nuclear localization.
Binding of mVP24 to Keap1 Kelch was further evaluated
by isothermal titration calorimetry (ITC), which measures heat mVP24 Expression Activates ARE-Directed Gene
generated by these exothermic interactions. ITC results Expression
confirmed that Keap1 Kelch binds the Nrf2 Neh2 domain with Stimuli that disrupt the Nrf2-Keap1 interaction and promote
high affinity (KD = 170 ± 60 nM) and stoichiometry (n = 0.46) Nrf2 nuclear localization activate expression of ARE genes (re(Figure 2A) and support a stoichiometry of 2:1 for Kelch binding viewed in Magesh et al., 2012). We therefore assessed the
to Neh2 with thermodynamic parameters similar to those previ- ability of wild-type or mutant mVP24s to activate an ARE lucifously reported by Tong et al. (2006). Assays under similar condi- erase reporter gene. Cellular Keap1-interacting protein p62, a
tions for Kelch-mVP24 resulted in a KD of 158 ± 20 nM (Figure 2B) previously described activator of Nrf2, served as a positive
with a binding stoichiometry of 1:1.
control (Komatsu et al., 2010; Lau et al., 2010). Expression of
To gain additional mechanistic insight, we performed com- mVP24 induced the ARE reporter to similar levels as p62 (Figpetition pull-down experiments using wild-type mVP24, eVP24, ure 3A). In contrast, mVP24 linker mutant and mVP24 G211A/
and eVP24 K-loop, which were designed based on the mVP24 E212A did not activate the ARE promoter. mVP24 D205A/
structural model (Figures S2A–S2C). We established the basal E207A did activate the ARE promoter but to a lesser extent
binding conditions for the Kelch and Neh2 interaction by pull- than wild-type mVP24, reflecting the residual binding activity
down (Figure S2D) as well as Kelch binding to mVP24 of this mutant for Keap1 (Figure 3A). Therefore, Nrf2 activation
(Figure S2E) and examined the ability of recombinant eVP24 correlates with Keap1-mVP24 binding activity (Figure 1F). In a
(Figure S2F) and eVP24 K-loop (Figure S2G) to bind the Keap1 separate experiment, expression of Nrf2 alone resulted in
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(Figure 3F).

greater than 100-fold ARE reporter activation (Figure 3B).
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interaction with Keap1 has functional consequences because
it can trigger Nrf2-dependent transcriptional activity in a
K-loop-dependent manner.
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Figure 4. MARV Infection Upregulates the
Nrf2 Antioxidant Pathway
(A and B) THP-1 cells were infected with MARVAng or Zaire EBOV (moi = 3) and subjected
to expression analysis by mRNA sequencing
(mRNA-seq).
(A) Heatmap displaying the expression profile of 30
Nrf2-activated genes (Chorley et al., 2012). Red
indicates upregulated genes (maximum induction,
8.55-fold relative to mock-infected cells). Green
indicates downregulated genes (lowest value, 0.2fold relative to mock-infected cells). Gray indicates
genes undetected in the mRNA-seq.
(B) mVP24 and eVP24 mRNA expression levels
represented as median nucleotide coverage.
(C) THP-1 cells were infected with MARV-Ang or
MARV-Mus (moi, 1) and subjected to qRT-PCR.
Values were normalized to RPS11. Mock sample
contains a single replicate; MARV-Ang and MARVMus represent the mean and SEM of triplicate
samples.
See also Figure S4.

10

20
0

0

M
oc
k
AR
VA
M
A R ng
VM
us

CLIP4CTSC-

1

Relative copy #
(normalized to Rps11)

KIFC2SQSTM1-

10000

1000

FTH1SRXN1MSCNQO1DUSP5TXNRD1N4BP2L2-

eVP24

mVP24

24

MARV Infection Induces the Expression of
Nrf2-Responsive Genes
mVP24 activates Nrf2 via interaction with Keap1, but eVP24
does not, suggesting that MARV but not EBOV infection should
induce an ARE response. To test this hypothesis, we profiled the
expression of select ARE genes in THP-1 cells following MARV
Angola strain (MARV-Ang) or Zaire EBOV infection (multiplicity
of infection [moi], 3). A substantial number of ARE genes were
upregulated in MARV-infected THP-1 cells as the infection progressed and mVP24 mRNA levels increased (Figures 4A and
4B). Although a few ARE genes were upregulated by EBOV infection, the response was not as global as was seen with MARV,
and the response did not correlate well with eVP24 expression
(Figures 4A and 4B). The mVP24 K-loop sequence is conserved
among MARV strains, suggesting that ARE activation should
also be shared between MARV strains. Indeed, induction of
two representative ARE genes, heme oxygenase 1 (HO-1) and
GCLM, was demonstrated by qRT-PCR following infection of
THP-1 cells with MARV-Ang or Musoke (MARV-Mus) (Figure 4C).
Interestingly, HO-1 is highly upregulated during MARV infection
(Figure 4A), and a recent study has indicated that EBOV replication/transcription is inhibited by HO-1 expression (Hill-Batorski
et al., 2013). However, using a MARV minigenome assay, we
did not detect any inhibition following HO-1 overexpression (Figure S4; see Supplemental Results for further details), suggesting
that upregulation of this ARE may not impair MARV replication.
DISCUSSION
The host antioxidant response has been increasingly recognized
as relevant to virus infections. Here, we demonstrate a direct,
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high-affinity interaction between mVP24
and the Kelch domain of the human and
bat Keap1, a major negative regulator of
antioxidant responses (see also Supplemental Discussion on bat Keap1). This
interaction, for which we define a critical role for the mVP24
K-loop sequence, can disrupt Nrf2-Keap1 interaction and induce
a cytoprotective state through transcriptional activation of the
ARE promoter. Although other viruses have previously been
demonstrated to activate antioxidant responses, the mechanisms of activation appear indirect, with virus infection triggering
oxidative stress or other cellular signaling pathways that stimulate Nrf2 nuclear accumulation (Burdette et al., 2010; Cho
et al., 2009; Ivanov et al., 2011; Kesic et al., 2011; Lee et al.,
2013; Schaedler et al., 2010). In contrast, the direct interaction
between mVP24 and Keap1 provides compelling evidence
that viruses have evolved mechanisms to engage the cellular
antioxidant response as part of their replication strategy.
Keap1-Nrf2 interaction is required for negative regulation of
the antioxidant response. A number of stimuli, such as oxidative
stress, that perturb the Keap1-Nrf2 interaction stabilize Nrf2,
allowing it to accumulate in the nucleus where it binds AREs
and cooperates with other factors to activate ARE-containing
promoters (Dinkova-Kostova et al., 2002; Zhang and Hannink,
2003). In addition, the interaction of the Keap1 Kelch domain
with p62, an autophagy factor that functions in the clearance
of polyubiquitinated complexes, activates Nrf2 through the
disruption of binding via the lower-affinity Keap1 binding site
on Nrf2 (Komatsu et al., 2010; Lau et al., 2010). We demonstrated
that the mVP24-Keap1 interaction requires the Keap1 Kelch
domain, as is true for many other Keap1 interactors (Kim et al.,
2010; Komatsu et al., 2010; Lo and Hannink, 2006; Niture and
Jaiswal, 2011). Our data further suggest that the interaction of
mVP24 with Keap1 can disrupt the high-affinity Nrf2-Keap1
binding site, leading to the subsequent nuclear localization of
Nrf2 and activation of the antioxidant response.
M
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The structural basis for the Keap1 Kelch interaction with peptides derived from several cellular Keap1 binding partners,
including Nrf2, p62, and prothymosin a, was previously
described by Komatsu et al. (2010), Lo et al. (2006), and Padmanabhan et al. (2008). These peptides bind the bottom of the
Keap1 b sheet propeller, which forms a basic pocket, in part
through electrostatic interactions with Keap1 arginine residues.
Common features of the binding peptides include acidic residues along with a GE motif (Komatsu et al., 2010; Lo and Hannink, 2006). Data obtained with mutated mVP24 K-loop acidic
residues and the GE motif support a similar mode of binding
for mVP24, although we cannot exclude a contribution of other
parts of mVP24. Consistent with a model where the mVP24
loop and the acidic residues within the loop make analogous
contacts with the Keap1 Kelch domain, substitution of Keap1
R415 to alanine abrogated Keap1-mVP24 interaction.
It is striking that MARVs and EBOVs differ in their interaction
with the ARE response (see Supplemental Discussion for details). Although there are no structures of mVP24, several structures of eVP24s, including Sudan and Reston EBOVs (sVP24 and
rVP24) (Zhang et al., 2012) as well as Zaire EBOV (eVP24), are
available (Figure 2; PDB 4M0Q). In order to evaluate the
mVP24 structure, we used the eVP24 structure, which was
most complete as the basis for the Phyre2-threading model
of mVP24. In the mVP24 model, the K-loop contains the
DIEPCCGE sequence, a sequence that is not conserved between mVP24 and eVP24 but shows similarity to motifs of other
Keap1-interacting ‘‘GE motifs.’’ Replacement of the K-loop residues with a heterologous linker sequence or mutation to alanine
of the D205 and E207 or of G211 and E212 was sufficient to
greatly reduce or abrogate binding, although it should be
acknowledged that the nuclear localization confounds interpretation of the G211A/E212A mutant data. That the DIEPCCGE
loop is central to binding is confirmed by the fact that transfer
of the loop to eVP24, which otherwise does not interact with
Keap1, confers binding activity. Furthermore, wild-type mVP24
effectively competes with Nrf2 for binding to Keap1 in vitro and
dissociates GFP-Nrf2 from Flag-Keap1 in a K-loop-dependent
manner. These observations suggest a mechanism by which
mVP24 activates an ARE transcriptional response. Interestingly,
the mVP24 DIEPCCGE sequence diverges from other Keap1
binding motifs, such as the so-called ETGE motif of Nrf2
(DEETGE), with ‘‘PCC’’ inserted between ‘‘GE’’ and more
amino-terminal acidic residues. The presence of the Cys residues is intriguing given that Keap1-Nrf2 interactions are regulated by oxidation. Whether these residues, which are not
present in other Keap1-interacting motifs, play an important
role in the mVP24-Keap1 interaction will be the subject of future
studies.
In addition to the ARE response, Keap1 regulates other stressinduced cell survival pathways through interaction of its Kelch
domain with a variety of proteins, including PGAM5, IKKb, and
p62 (Kim et al., 2010; Komatsu et al., 2010; Lau et al., 2010;
Lee et al., 2009; Lo and Hannink, 2006; Niture and Jaiswal,
2011). mVP24 disruption of these Keap1 interactions could
inhibit apoptosis, activate NF-kB-mediated cell survival pathways, and influence autophagy (Fan et al., 2010; Kim et al.,
2010; Lee et al., 2009; Niture and Jaiswal, 2011). Furthermore,

the stable interaction of mVP24 and Keap1, which did not detectably influence mVP24 expression levels, might allow the
recruitment of Keap1 and binding partners for new functions.
Further study is therefore required to fully elucidate the impact
of the mVP24-Keap1 interaction upon MARV infection.
EXPERIMENTAL PROCEDURES
CoIP
Twenty-four hours posttransfection with the indicated plasmids, HEK293T
cells were lysed in NP-40 lysis buffer (50 mM Tris [pH 7.5], 280 mM NaCl,
0.5% Nonidet P-40, 0.2 mM EDTA, 2 mM EGTA, 10% glycerol, and protease
inhibitor [cOmplete; Roche]). Anti-FLAG M2 magnetic beads or anti-HA beads
(Sigma-Aldrich) were incubated with lysates for 1 hr at 4 C, washed five times
in NP-40 lysis buffer, and eluted using either 33 FLAG peptide (Sigma-Aldrich)
or by boiling in sample loading buffer.
Activation of Nrf2
For ARE reporter gene assays, a commercially available reporter gene,
pGL4.37[luc2P/ARE/Hygro] (ARE) (Promega), was cotransfected with a constitutively expressed Renilla luciferase reporter plasmid (pRL-tk; Promega), and
the indicated protein expression plasmids. At 18 hr posttransfection, a dual
luciferase reporter assay (Promega) was performed in triplicate, and firefly
luciferase values were normalized to Renilla luciferase values. Statistical significance was assessed with one-way ANOVA using Tukey’s test for comparisons to the control. Protein expression levels were assessed by western
blot. Levels of endogenous NQO1, GCLM, or HO-1 mRNAs were assessed
by qRT-PCR, and NQO1 protein levels were assessed by western blot using
a commercially available antibody (Santa Cruz Biotechnology).
Virus Infections
The following infections were performed under BSL-4 conditions at the
Galveston National Laboratory. THP-1 cells were differentiated overnight
with 100 nM PMA and infected with MARV-Ang (moi = 3 or 1), MARV-Mus
(moi = 1), or EBOV (moi = 3). Viral total RNA was extracted with TRIzol at the
indicated time points for analysis by deep sequencing or qRT-PCR. For
deep sequencing, mRNA was purified with Oligo(dT) magnetic beads (Invitrogen). cDNA libraries were generated (NEBNext; New England Biolabs) and
sequenced on the Illumina HiSeq 2500 platform, and relative expression for
each gene of interest was determined. For qRT-PCR, cDNA was generated
with Oligo(dT) primers, and relative expression for each gene of interest was
determined by normalizing to the indicated housekeeping gene. Refer to Supplemental Experimental Procedures for additional details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Results, Supplemental
Discussion, Supplemental Experimental Procedures, four figures, and one
table and can be found with this article online at http://dx.doi.org/10.1016/j.
celrep.2014.01.043.
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Extended Results
Molecular modeling of mVP24 based on an eVP24 crystal structure. Filoviral VP24 proteins
show significant sequence homology (data not shown). In order to gain insight into the structural
basis for filoviral VP24 functions, we solved the crystal structure of the highly pathogenic Zaire
EBOV VP24 protein (eVP24) (Fig. S2, and Table S1 for structure statistics).

Overall, the

eVP24 structure adopts a conformation that is similar to those previously observed for the
Reston virus and Sudan virus VP24 proteins (rVP24 and sVP24) (Zhang et al., 2012). In
addition to the increased resolution to 1.92Å (compared to 2.0 Å and 2.1 Å rVP24 and sVP24
structures, respectively), many loop regions are experimentally well-defined in the eVP24
structure, particularly the residues that correspond to the mVP24 K-loop. For this reason, we
chose to use the eVP24 structure for 1:1 threading using the mVP24 sequence. The resulting
structure, shown in Fig. 1E, reveals that the critical K-loop of mVP24 is solvent exposed and is
likely available to interact with the Keap1 Kelch domain. Previous studies of Keap1 Kelch
interacting partners, such as Neh2 DLG, Neh2 ETGE, and p62, show that the peptide region
binding to Kelch must be in an unfolded conformation (Cino et al., 2013). Consistent with these
previous observations, our threaded model of mVP24 K-loop is predicted to be in a flexible
conformation. While this data agrees with our binding studies and in vivo observations,
additional structural data are required to experimentally confirm this observation.
mVP24 relocalizes Nrf2 to the nucleus. To determine whether interaction of mVP24 with the
Keap1 Kelch domain activates Nrf2, a GFP-Nrf2 fusion protein was expressed alone or in the
presence of Flag-Keap1 and HA-tagged wild-type mVP24, mutant mVP24 or wild-type or
chimeric eVP24s. Over-expression of Nrf2, which overcomes endogenous Keap1, resulted in
nuclear localization of GFP-Nrf2 (Fig. S1). Co-expression of Keap1 retained most of the Nrf2 in
the cytoplasm. Additional expression of mVP24 restored Nrf2 nuclear localization in 72% of
cells, suggesting disruption of the Nrf2-Keap1 interaction (Fig. S1). mVP24 linker, mVP24
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D205A/E207A or mVP24 G211A/E212A did not prevent Keap1 retention of Nrf2 in the
cytoplasm (Fig. S1). Expression of eVP24 also did not alter the cytoplasmic localization of Nrf2,
but eVP24 K-loop resulted in 38% of cells having nuclear Nrf2 (Fig. S1). eVP24 DIEPCCGE,
which precipitated less efficiently with Keap1 (Fig. 1G), was unable to relocalize Nrf2 to the
nucleus (Fig. S1).

Cumulatively, these data correlate mVP24-Keap1 interaction with the

nuclear accumulation of Nrf2 and demonstrate that the presence of mVP24 can dissociate Nrf2
from Keap1.
Impact of HO-1 expression on a MARV minigenome assay. A recent study indicated that
HO-1 expression inhibits EBOV replication/transcription (Hill-Batorski et al., 2013). As HO-1 is
highly induced by MARV (Fig. 4A), we asked whether HO-1 expression affects MARV
replication/transcription. When HO-1 was expressed in increasing amounts in the context of a
MARV minigenome assay, no inhibitory effect was seen relative to a GFP over-expresion
control (Fig. S4).

These results suggest that HO-1 expression may not affect MARV

replication/transcription in the manner recently described for EBOV.
Extended Discussion
We demonstrate that mVP24 interacts comparably with bat Keap1 and human Keap1 (Fig. 1).
The conservation of the mVP24 interaction with bat Keap1 is consistent with a role for this
interaction in MARV reservoir hosts. Although the Egyptian fruit bat (Rousettus aegyptiacus) is
the most definitive host species for MARV, its Keap1 sequence was not available. We were
able to obtain from public databases the predicted sequences of an Old World fruit bat
(Pteropus alecto) and a New World insectivorous bat (Myotis lucifugus). Each of these was
highly conserved across its entire length with human Keap1. Therefore, we presume that the
Egyptian fruit bat Keap1 will also be highly conserved relative to human Keap1. Based on the
M. lucifugus Keap1 sequence, we cloned Keap1 from an available Myotis velifer incautus cell
line and demonstrated that the interaction with mVP24 is conserved. Further, because bat
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Keap1 is very similar to human Keap1, we were able to test the functional implications of
mVP24 for bat Keap1 in human cells, confirming that mVP24 can disrupt bat Keap1-(human)
Nrf2 interaction. Pathogenesis of MARV in humans is almost certainly different than in the
reservoir host. It is worth considering, therefore, that the mVP24-Keap1 interaction may have
unique consequences in bats versus humans.
Oxidative stress responses upon MARV infection have not been characterized. We
demonstrate that the expression of mVP24 as well as MARV infection can upregulate a number
of Nrf2 targeted genes, whereas EBOV infection did not result in a comparable induction over
time. Although the response of ARE genes to MARV versus EBOV infection is clearly different,
not all of our chosen ARE genes were upregulated by MARV infection. Our list of ARE genes
was based on 30 genes that were induced in lymphoid cells treated with the dietary
isothiocyanate, sulforaphane (SFN) (Chorley et al., 2012). As some studies report that different
activators of Nrf2 can upregulate different subsets of genes in the same cell type (Lau et al.,
2013), it may not be surprising that all 30 genes did not increase. As would be expected for a
functionally significant interaction, two different strains of MARV were able to upregulate an
ARE response, as demonstrated by induction of two of the best characterized ARE genes, HO-1
and GCLM. Numerous effects of HO-1 expression have been described, including protection
from apoptosis, modulation of the NFκB pathway and activation of the p38 mitogen-activated
protein kinase (MAPK) pathway (reviewed in (Gozzelino et al., 2010)). GCLM is involved in the
synthesis of glutathione, one of the major antioxidants in the cell (Ma, 2013). We hypothesize
that upregulation of these, and other Nrf2 targeted genes, will enhance survival of MARVinfected cells, facilitating viral production.
Our data demonstrate that MARV and EBOV differ with regard to how they interact with
the Nrf2 pathway. This is consistent with other functionally significant differences between these
filoviral genera. Previously important differences have been described between MARV and
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EBOV, including different mechanisms by which they inhibit innate immune responses. For
example, eVP24 has been shown to interact with members of the NPI-1 subfamily of
karyopherin alpha proteins to inhibit interferon signaling, but MARV VP24 does not (Mateo et
al., 2009; Reid et al., 2006; Reid et al., 2007; Valmas et al., 2010). While MARV VP40 inhibits
IFN signaling by blocking Jak1 function, EBOV VP40 does not (Valmas et al., 2010). Further,
differences in the binding of MARV and EBOV VP35s to dsRNA suggest differences in how
each virus antagonizes RIGI-like receptor signaling (Kimberlin et al., 2010; Leung et al., 2009;
Leung et al., 2010a; Leung et al., 2010b; Ramanan et al., 2012b). Our data provides further
evidence that there are significant differences between MARV and EBOV, despite the two
viruses being in the same family.
Interestingly, HO-1 was recently reported to inhibit EBOV replication and inhibit an
EBOV minigenome assay (Hill-Batorski et al., 2013). When we tested HO-1 expression for
inhibitory activity towards a MARV minigenome assay, no suppressive activity was detected
(Fig. S4). Inhibition of ARE responses by EBOV may suppress an anti-EBOV activity of HO-1.
If MARV is resistant to the effects of HO-1, this may allow induction of HO-1 and other Nrf2responsive genes for the purpose of enhancing cell survival.
The full implications of mVP24 interaction with Keap1 and a complete testing of the
hypothesis that the interaction serves primarily to activate a cytoprotective state will require
further study (see Discussion in main text). Nonetheless, some conclusions can be made. The
induction of a cytoprotective state through the upregulation of ARE gene transcription would
require the efficient translation of these cellular mRNAs. Because filoviruses do not shut down
host cell transcription or protein synthesis, the ARE transcriptional response in MARV infected
cells should lead to expression of cytoprotective proteins (Elliott et al., 1985; Hartman et al.,
2008). Our hypothesis requires that infected cells survive long enough that virus yield can be
enhanced. While little is known about MARV replication in the reservoir bat host, in many
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human cell lines, the filovirus replication cycle is not particularly fast, and cells infected with
EBOV have even been shown to undergo mitosis, demonstrating that these infections do not
completely disrupt cellular processes (Hoenen et al., 2012). Therefore, the cytoprotective
response would seem to have sufficient opportunity to be established during MARV infection.
Also to be determined is whether other MARV proteins may modulate mVP24-Keap1
interaction.
It is notable that eVP24 seems to exert an inhibitory effect towards Nrf2-induced gene
expression (Fig. S3D). The basis for this inhibition is unclear. This inhibitory activity may
explain why the eVP24 chimeras containing mVP24 K-loop sequences do not activate ARE
gene expression as well as wildtype mVP24 (Fig. S3B and C). Presumably, these eVP24
chimeras, which bind Keap1 efficiently, have two competing functions, an Nrf2 activating
function (due to the interaction with Keap1) and an as yet unexplained inhibitory activity.
Filoviral VP24s also interact with filoviral VP35 and NP proteins in viral nucleocapsids,
modulate viral RNA synthesis and play roles in viral budding (Bamberg et al., 2005; Beniac et
al.; Bharat et al., 2012; Bharat et al., 2011; Hoenen et al., 2006; Huang et al., 2002; Mateo et
al.; Noda et al., 2006; Watanabe et al., 2007; Wenigenrath et al., 2010). Further study will be
required to understand the interplay and functional consequences of the various mVP24
interactions.

A more complete understanding of these issues may suggest novel antiviral

approaches to these deadly viruses.

Extended Experimental Procedures
Cells
HEK293T, HeLa and Myotis velifer incautus (ATCC, CRL-6012) cell lines were maintained in
Dulbecco’s minimal essential medium supplemented with 10% fetal bovine serum (FBS) and
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cultured at 37°C and 5% CO2. BSRT7 cells were grown in the same medium supplemented with
1% G418. THP-1 cells were maintained in RPMI supplemented with 10% FBS, 1%
penicillin/streptomycin, 1% L-glutamine, 1% sodium pyruvate and 1% beta mercaptoethanol.
Plasmids
The plasmids encoding Flag and HA tagged mVP24 and eVP24 in the pCAGGS vector were
previously described (Valmas et al., 2010). Mutations to mVP24 were made using overlapping
PCR and cloned into pCAGGS vector containing a N-terminal Flag tag. Mutations of residues to
alanines were done using the GCT codon. The serine/glycine linker, SGGSGGSG, in the
mVP24

linker

mutant

was

inserted

into

mVP24

using

the

forward

primer

5’-

TCCGGAGGCTCAGGTGGCAGCGGAacagtcctctcagaatcag-3’ and the reverse primer 5’TCCGCTGCCACCTGAGCCTCCGGAaatcctcctgacttccac-3’ (the serine/glycine linker sequence
is in capital letters). mVP24 residues 205-DIEPCCGE-212 were inserted into eVP24 between
residues 202 and 211 using overlapping PCR, making eVP24 DIEPCCGE. mVP24 residues
202-RRIDIEPCCGETVLSESV-219 were inserted into eVP24 between residues 201 and 218
using overlapping PCR, making eVP24 K-loop. pcDNA Flag tagged Keap1 was purchased from
Addgene (Addgene plasmid 28023(Fan et al., 2010)) and cloned with an N-terminal Flag tag
into pCAGGS. A series of domain deletion mutants of Keap1 in Flag tagged pCAGGS were
constructed by PCR. Keap1 ΔNTR construct lacks the first 60 amino acids, Keap1 ΔIVR lacks
amino acids 180-314 and Keap1 ΔKelch/CTR lacks amino acids 315-624. Keap1 Kelch/CTR
contains amino acids 315-624. Flag tagged Keap1 R415A was generated using overlapping
PCR and the GCC codon to make the mutation to alanine. pcDNA3Myc tagged Nrf2 was
purchased from Addgene (Addgene plasmid 21555(Furukawa and Xiong, 2005)) and cloned
with an N-terminal HA tag or Flag tag into pCAGGS or into a pCAGGS GFP fusion construct.
pcDNA4/TO HA p62 was purchased from Addgene (Addgene plasmid 28027). The
pGL4.37[luc2P/ARE/Hygro] (ARE) reporter was purchased from Promega. HO-1 was cloned
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using cDNA from THP-1 isolated RNA and the forward primer 5’-atggagcgtccgcaacccgac-3’ and
reverse primer 5’-tcacatggcataaagccctac-3’ and inserted into pCAGGS such that it is expressed
with an N-terminal HA tag. Bat-Keap1 and bat-Kelch were amplified from Myotis velifer incautus
cell mRNA. For full length Keap1, forward primer 5’-atgcagccggaacccgggcc-3’ and for the Kelch
domain forward primer 5’-caggtgatgccctgccgg-3’ were used. Each construct was amplified by
using the same reverse primer 5’-tcaacaggtacagttctgctgg-3’. These amplicons were cloned into
pCAGGS vector such that they produced a protein with an N-terminal Flag tag. MARV L was
synthesized and cloned into pCAGGS such that it expressed with an N-terminal Flag tag. FlagVP35 and Flag-NP have been previously described (Ramanan et al., 2012a).
Antibodies
Monoclonal mouse anti-FLAG M2 antibody, polyclonal rabbit anti-Flag antibody, monoclonal
mouse anti-HA antibody and a polyclonal rabbit anti-HA antibody were purchased from SigmaAldrich. A mouse monoclonal anti-NQO1 (A180) antibody was purchased from Santa Cruz.
Alexa Fluor anti-mouse 555 and Alexa Fluor anti-rabbit 633 were purchased from Invitrogen.
Isothermal Titration Calorimetry.

All proteins were extensively dialyzed against buffer

containing 10 mM HEPES (pH 7.0.), 150 mM sodium chloride, and 2 mM tris(2carboxyethyl)phosphine and degassed before use. 110 µM Keap1 Kelch domain protein was
loaded into a stirring syringe and injected into a sample cell containing 5 uM Nrf2 Neh2 domain
protein or 7 µM mVP24 protein. Binding data were analyzed using Origin (OriginLab). The
binding stoichiometry (n), enthalpy change (ΔH), entropy change (ΔS), and binding association
constant (Ka) were obtained from the experimental titration curve. Dissociation constants (KD)
were calculated from the Ka.
Immunofluorescence
HeLa cells grown on glass coverslips were transfected with indicated plasmids using
Lipofectamine 2000 (Invitrogen). At 24 hours post transfection, cells were fixed using 4%
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paraformaldehyde and permeabilized using 0.1% Triton X-100. Cells were stained using the
primary antibodies to Flag M2 (dilution 1:400) and HA (dilution 1:400) and secondary antibodies
conjugated to Alexa Fluor 555 or Alexa Fluor 633 (Life Technologies) (dilution 1:2000). Images
were taken using Zeiss Axioplan 2IE fluorescence microscope. The percent of cells containing
nuclear Nrf2 localization was determined by counting cells in four individual fields of view.
Cell viability assay
HEK293T cells (10,000) were transfected using Lipofectamine 2000 (Invitrogen) with pCAGGS,
Flag-Nrf2, mVP24 or mVP24 G211A/E212A plasmids. At 24 hours post transfection cells were
treated with a vehicle control (ethanol) or 5uM of menadione (Sigma) for three hours, after
which cells were assayed using CellTiter-Glo luminescent cell viability assay (Promega). The
assay was performed with six replicates; error bars represent the SEM. Statistical analysis was
done by one-way ANOVA using Tukey’s test, *p<0.05.
Western Blotting
Lysates were run on 10% acrylamide SDS/PAGE gels (Lonza) and transferred to
polyvinylidenedifluoride membrane. The membranes were probed with anti-FLAG M2, anti-HA
and/or anti-NQO1 and developed using Western Lightning ECL kit (Perkin-Elmer).
RNA extractions and qRT-PCR
HEK293T cells (2.5 x 105) were transfected using Lipofectamine 2000 (Invitrogen) with the
indicated plasmids. Cells were harvested at 24 hours post transfection. RNA was extracted
using the RNeasy Kit (Qiagen), and cDNA was generated using SuperScript III Reverse
Transcriptase (Invitrogen). Primers used for qRT-PCR were previously described (Lau et al.,
2010). Transfections were performed in triplicate and the data were expressed as relative
mRNA levels normalized to RPS11.
MARV minigenome assay
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BSRT7 cells (2.5 x 105) were transfected in triplicate using Lipofectamine 2000 (Invitrogen) with
the MARV minigenome plasmid (encoding Renilla luciferase) (200ng), a plasmid with firefly
luciferase under the control of the T7 promoter as a transfection control (10ng), and plasmids
encoding MARV L (500ng), MARV VP35 (125 ng) and MARV NP (500 ng). HA-HO-1 or GFP
was co-transfected at increasing concentrations (100 ng, 500 ng and 1 µg). Forty-eight hours
post-transfection a Dual luciferase assay (Promega) was performed. Renilla luciferase values
were normalized to firefly luciferase values. Error bars represent the mean and SEM of triplicate
samples, and statistical significance was assessed by a one-way ANOVA comparing bars as
indicated using Tukey’s test.
eVP24 cloning, expression, and purification
eVP24 was subcloned into a modified pET15b vector (Novagen) and sequenced before use.
eVP24 was overexpressed as an MBP fusion protein in BL21(DE3) E. coli cells (Novagen) in LB
medium. Protein expression was induced at an OD600nm of 0.6 with 0.5 mM IPTG (Sigma) at
18°C. Cells were harvested, resuspended in buffer containing 25 mM sodium phosphate pH 7.5,
250 mM NaCl, 20 mM imidazole, and 5 mM 2-mecaptoethanol, and lysed using an EmulsiFlexC5 homogenizer (Avestin). Cell lysate was clarified by centrifugation at 30,000 x g at 4 °C for 30
min. eVP24 protein was purified using a series of chromatographic columns. The MBP fusion
tag was cleaved with TEV protease prior to loading on a Superdex 75 gel filtration column (GE
Healthcare). Sample purity was determined by SDS-PAGE.
eVP24 crystallization, x-ray data collection, and structure determination
Initial crystallization conditions were obtained using commercially available screens (Hampton
Research) and by the hanging drop method. Initial hits were further optimized using in-house
reagents. Diffraction quality crystals were obtained in 150 mM MES pH 5.4, 20% Jeffamine M600 pH 7.0, 50 mMCaCl, and 6 mMLiCl¬2 using 15 mg/ml of eVP24 protein. Crystals were cryoprotected with 25% glycerol prior to vitrification. X-ray diffraction data were collected at the
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Advanced Light Source (ALS) beamline 4.2.2 (Berkeley, CA) initially and the final data were
collected at the Advanced Photon Source (APS) beamline 19ID (Argonne, IL). The best eVP24
crystal diffracted to 1.92 Å. Diffraction data was processed using HKL3000 (Otwinowski and
Minor, 1997). The structure was solved by molecular replacement with Molrep using PDB ID
3VNE and 4D9O as the search model and refined using REFMAC5 (Vagin et al, 2004). Manual
model building was done in COOT (Emsley et al, 2004) with additional refinement using
PHENIX1.8.2 (Adams, P.D, et al, 2010). The structure quality was assessed using MolProbity
(Davis I. W et al, 2007).
In vitro pull-down assays.
Pull-down assays were performed in buffer containing 20 mMTris-HCl (pH 7.0), 50 mM sodium
chloride, and 2 mM tris(2-carboxyethyl)phosphine. MBP-fusion mVP24 protein was immobilized
on amylose resin prior to the addition of Keap1 Kelch domain and Nrf2 Neh2 domain. Bound
resin was washed extensively. Samples were visualized by Coomassie blue staining of SDSPAGE gels.
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Edwards et al. Supplemental Figures
Fig. S1. mVP24 co-localizes with Keap1 and expression relocalizes Nrf2 to the
nucleus, related to Figure 1. HeLa cells were transfected with plasmids for GFP-Nrf2,
Flag-Keap1 and/or HA-tagged VP24 proteins. Twenty-four hours post transfection, slides
were fixed and stained with anti-Flag antibody and anti-rabbit IgG Alexa Fluor 633 or
anti-HA antibody and anti-mouse IgG Alexa Fluor 555 to visualize protein localization.
Image is representative. The percent of cells with cytoplasmic vs. nuclear Nrf2 was
determined by counting cells in four individual fields of view for each sample.

Edwards et al. Figure S2

B

A

C
202

205

219

212

mVP24 --- R R I D I E P C C G E T V L S E S V --eVP24
D

202

217

--- Q E P D K S A M D I R H P G P V ---

E

F

G

Edwards et al. Supplemental Figures
	
  
Fig. S2. mVP24 K-loop residues in the eVP24 scaffold are sufficient to mediate
interactions between VP24 and the Keap1 Kelch domain, related to Figure 2. (A
and B) Alignment of the Phyre2 generated structural model of mVP24 (orange) based on
the eVP24 (purple) crystal structure (PDB ID 4M0Q). Residues in the K-loop are
highlighted and expanded in (B). mVP24 K-loop residues 205-212 are highlighted in red.
(C) Schematic representation of residues present in the loop regions of mVP24 and
eVP24 highlighted in (B). (D, E, F and G) Coomassie blue-stained SDS-PAGE of
pulldown assays of the Keap1 Kelch domain with: D. MBP-Nrf2 Neh2, E. MBP-mVP24,
F. MBP-eVP24, and G. MBP-eVP24 K-loop. Lanes from left to right correspond to
marker, amylose resin bound to MBP-tagged protein (double arrowheads), Keap1 Kelch
domain (single arrowhead) added to amylose resin bound to MBP-tagged protein, and
final bound amylose resin after washes.
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Fig. S3. Interaction of VP24 constructs with Keap1 activates ARE gene expression,
related to Figure 3. 293T cells were transfected with the ARE luciferase reporter
plasmid, a constitutively expressed Renilla luciferase plasmid, Flag-Nrf2, HA-Keap1 and
pCAGGS (empty vector) or Keap1 or bat-Keap1 and Flag mVP24 as indicated. At 18 hpt
luciferase activity was assayed. Western blots for HA and Flag are indicated. (B)
pCAGGS, HA-mVP24, eVP24, eVP24 DIEPCCGE or eVP24 K-loop were transfected in
triplicate in HEK293T cells. At 24 hpt, qRT-PCR was performed for the indicated mRNAs
and normalized to RPS11. (C) 293T cells were transfected with the indicated plasmids,
and 18 hpt endogenous NQO1 was measured by western blot. (D) The same assay
protocol as in (A) but with Flag-Nrf2, Keap1 and eVP24 transfected as indicated. (A, B
and D) represent the mean and SEM of triplicate samples, and statistical significance
was assessed by a one-way ANOVA comparing columns to the control (white bar) or as
indicated, ***p<0.001, **p<0.01 and *p<0.05.
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Fig. S4. MARV replication/transcription is not detectably affected by HO-1
expression, related to Figure 4. BSRT7 cells were transfected with the MARV
Renilla luciferase minigenome, firefly luciferase as transfection control, and MARV L,
VP35 and NP.

HA-HO-1 or GFP were co-transfected at increasing concentrations

(100ng, 500ng and 1ug). Forty-eight hpt luciferase activity was assayed. Bars represent
the mean and SEM of triplicate samples and statistical significance was assessed by a
one-way ANOVA comparing bars as indicated. n.s., no significance.

